Cargando…

Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies

[Image: see text] Macrocyclic Hedgehog (Hh) pathway inhibitors have been discovered with improved potency and maximal inhibition relative to the previously reported macrocycle robotnikinin. Analogues were prepared using a modular and efficient build-couple-pair (BCP) approach, with a ring-closing me...

Descripción completa

Detalles Bibliográficos
Autores principales: Dockendorff, Chris, Nagiec, Marek M., Weïwer, Michel, Buhrlage, Sara, Ting, Amal, Nag, Partha P., Germain, Andrew, Kim, Han-Je, Youngsaye, Willmen, Scherer, Christina, Bennion, Melissa, Xue, Linlong, Stanton, Benjamin Z., Lewis, Timothy A., MacPherson, Lawrence, Palmer, Michelle, Foley, Michael A., Perez, José R., Schreiber, Stuart L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469069/
https://www.ncbi.nlm.nih.gov/pubmed/23074541
http://dx.doi.org/10.1021/ml300172p
_version_ 1782246030031454208
author Dockendorff, Chris
Nagiec, Marek M.
Weïwer, Michel
Buhrlage, Sara
Ting, Amal
Nag, Partha P.
Germain, Andrew
Kim, Han-Je
Youngsaye, Willmen
Scherer, Christina
Bennion, Melissa
Xue, Linlong
Stanton, Benjamin Z.
Lewis, Timothy A.
MacPherson, Lawrence
Palmer, Michelle
Foley, Michael A.
Perez, José R.
Schreiber, Stuart L.
author_facet Dockendorff, Chris
Nagiec, Marek M.
Weïwer, Michel
Buhrlage, Sara
Ting, Amal
Nag, Partha P.
Germain, Andrew
Kim, Han-Je
Youngsaye, Willmen
Scherer, Christina
Bennion, Melissa
Xue, Linlong
Stanton, Benjamin Z.
Lewis, Timothy A.
MacPherson, Lawrence
Palmer, Michelle
Foley, Michael A.
Perez, José R.
Schreiber, Stuart L.
author_sort Dockendorff, Chris
collection PubMed
description [Image: see text] Macrocyclic Hedgehog (Hh) pathway inhibitors have been discovered with improved potency and maximal inhibition relative to the previously reported macrocycle robotnikinin. Analogues were prepared using a modular and efficient build-couple-pair (BCP) approach, with a ring-closing metathesis step to form the macrocyclic ring. Varying the position of the macrocycle nitrogen and oxygen atoms provided inhibitors with improved activity in cellular assays; the most potent analogue was 29 (BRD-6851), with an IC(50) of 0.4 μM against C3H10T1/2 cells undergoing Hh-induced activation, as measured by Gli1 transcription and alkaline phosphatase induction. Studies with Patched knockout (Ptch(–/–)) cells and competition studies with the Smoothened (Smo) agonists SAG and purmorphamine demonstrate that in contrast to robotnikinin, select analogues are Smo antagonists.
format Online
Article
Text
id pubmed-3469069
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-34690692012-10-14 Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies Dockendorff, Chris Nagiec, Marek M. Weïwer, Michel Buhrlage, Sara Ting, Amal Nag, Partha P. Germain, Andrew Kim, Han-Je Youngsaye, Willmen Scherer, Christina Bennion, Melissa Xue, Linlong Stanton, Benjamin Z. Lewis, Timothy A. MacPherson, Lawrence Palmer, Michelle Foley, Michael A. Perez, José R. Schreiber, Stuart L. ACS Med Chem Lett [Image: see text] Macrocyclic Hedgehog (Hh) pathway inhibitors have been discovered with improved potency and maximal inhibition relative to the previously reported macrocycle robotnikinin. Analogues were prepared using a modular and efficient build-couple-pair (BCP) approach, with a ring-closing metathesis step to form the macrocyclic ring. Varying the position of the macrocycle nitrogen and oxygen atoms provided inhibitors with improved activity in cellular assays; the most potent analogue was 29 (BRD-6851), with an IC(50) of 0.4 μM against C3H10T1/2 cells undergoing Hh-induced activation, as measured by Gli1 transcription and alkaline phosphatase induction. Studies with Patched knockout (Ptch(–/–)) cells and competition studies with the Smoothened (Smo) agonists SAG and purmorphamine demonstrate that in contrast to robotnikinin, select analogues are Smo antagonists. American Chemical Society 2012-08-30 /pmc/articles/PMC3469069/ /pubmed/23074541 http://dx.doi.org/10.1021/ml300172p Text en Copyright © 2012 American Chemical Society Terms of Use (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html)
spellingShingle Dockendorff, Chris
Nagiec, Marek M.
Weïwer, Michel
Buhrlage, Sara
Ting, Amal
Nag, Partha P.
Germain, Andrew
Kim, Han-Je
Youngsaye, Willmen
Scherer, Christina
Bennion, Melissa
Xue, Linlong
Stanton, Benjamin Z.
Lewis, Timothy A.
MacPherson, Lawrence
Palmer, Michelle
Foley, Michael A.
Perez, José R.
Schreiber, Stuart L.
Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies
title Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies
title_full Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies
title_fullStr Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies
title_full_unstemmed Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies
title_short Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies
title_sort macrocyclic hedgehog pathway inhibitors: optimization of cellular activity and mode of action studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469069/
https://www.ncbi.nlm.nih.gov/pubmed/23074541
http://dx.doi.org/10.1021/ml300172p
work_keys_str_mv AT dockendorffchris macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT nagiecmarekm macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT weiwermichel macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT buhrlagesara macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT tingamal macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT nagparthap macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT germainandrew macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT kimhanje macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT youngsayewillmen macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT schererchristina macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT bennionmelissa macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT xuelinlong macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT stantonbenjaminz macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT lewistimothya macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT macphersonlawrence macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT palmermichelle macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT foleymichaela macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT perezjoser macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies
AT schreiberstuartl macrocyclichedgehogpathwayinhibitorsoptimizationofcellularactivityandmodeofactionstudies